ClinicalTrials.gg
CompletedNCT00326118Updated Aug 24, 2018Results posted

Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

A Phase 3 interventional study of Haemophilus influenzae type b and meningococcal serogroup C (vaccine) and Priorix™ in Haemophilus Influenzae Type b and Neisseria Meningitidis, sponsored by GlaxoSmithKline. Completed at 7 sites in Australia. Open to participants aged 12 Months to 18 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-24.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
433
Allocation
Randomized
Ages
12 Months to 18 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.

Enrollment
42nd of 80
433 · median 445
Started
2006
with 13 others
Phase 3
48 of 82
none open now
Registered
27th of 82
by date

Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 42nd largest by enrollment of the 80 interventional ones that give a count, is one of 14 that started in 2006, is one of 48 in phase 3, and was the 27th registered.

Haemophilus Infections

176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.

Browse Haemophilus Infections studies →

Open to participants now

None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →

Who these studies take

Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 12 Months to 18 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 82 studies in Haemophilus Infections by GlaxoSmithKline as a file.
02

Study summary

The purpose of the primary phase of the study is to demonstrate the non-inferiority of a single dose of GSK Biologicals' Haemophilus influenzae type b and meningococcal C (Hib-MenC) conjugate vaccine when given in the second year of life to subjects primed in infancy with a Hib vaccine, but not with a meningococcal serogroup C vaccine, versus commercially available Hib and MenC vaccines.

In the extension phase, at Years 1, 2, 3, 4 \& 5, one blood sample is taken at each year to follow the antibody persistence up to 5 years after vaccination. No additional vaccine is administered during the extension phase. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

Read the detailed description

This multicenter study is open and has 2 treatment groups with Hiberix™ + a commercially available MenC vaccine as active controls. Priorix™ is given concomitantly in both groups. In the primary phase, two blood samples are taken from all subjects for immunogenicity analyses: before and one month after vaccination. In the extension phase, at Year 1, 2, 3, 4 \& 5, one blood sample is taken at each year to follow the antibody persistence up to 5 years after vaccination. No additional vaccine is administered during the extension phase.

03

Conditions studied

  • Haemophilus Influenzae Type b
  • Neisseria Meningitidis

Keywords

  • Meningococcal serogroup C diseases
  • H.influenzae type b diseases
04

Who can participate

Ages eligible
12 Months to 18 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Primary phase:

  • Subjects whom the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.
  • A male or female between, and including, 12 and 18 months of age at the time of vaccination.
  • Written obtained from the parent or guardian of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Previously completed routine childhood vaccinations to the best of his/her parents'/guardians knowledge.
  • Having completed primary vaccination with two doses of Haemophilus influenzae type b outer membrane protein (Hib-OMP) containing vaccine OR three doses of diphtheria, tetanus, acellular pertussis and Haemophilus influenzae type b (DTPa/Hib) containing vaccine at least 6 months before the study start.

Long-term persistence phase:

  • Having participated in the vaccination study 106445

Exclusion criteria

Exclusion Criteria:

For the primary vaccination phase:

  • Use of any or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) or planned administration of immuno-suppressants or other immune-modifying drugs within six months prior to vaccination.
  • Planned administration/administration of a vaccine not foreseen by the protocol during the period starting from 30 days before vaccination and ending 30 days after vaccination.
  • Administration of a meningococcal vaccine not foreseen by the study protocol during the period starting at birth and ending at first dose.
  • Previous administration of a booster dose of Hib vaccine.
  • Previous vaccination against measles, mumps, rubella.
  • History of H. influenzae type b, meningococcal serogroup C and/or confirmed measles, mumps or rubella diseases.
  • Known exposure to measles, mumps or rubella within 30 days prior to the start of the study.
  • Any confirmed or suspected or immunodeficient condition, including infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Major congenital defects or serious chronic illness.
  • History of neurological disorders or more than one episode of febrile convulsion.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

Additional exclusion criteria for the long-term persistence phase: to be checked each year.

  • Previous administration of a booster dose of Hib, meningococcal serogroup C vaccines.
  • History of H. influenzae type b, meningococcal serogroup C diseases.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
433 participants (actual)

Study arms

  • Active comparator
    Meningitec + Hiberix Group

    Subjects received a single dose of Meningitec™ vaccine co-administered with Hiberix™ and Priorix™ vaccines. The Meningitec vaccine was administered intramuscularly in the left deltoid region, the Hiberix vaccine was administered intramuscularly in the left thigh region and the Priorix vaccine was administered subcutaneously in the right upper arm.

    Biological: Priorix™ · Biological: Hiberix™ · Biological: Meningitec™

  • Experimental
    Menitorix Group

    Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine. Menitorix vaccine was administered intramuscularly in the left deltoid region and the Priorix vaccine was administered subcutaneously in the right upper arm.

    Biological: Haemophilus influenzae type b and meningococcal serogroup C (vaccine) · Biological: Priorix™

Interventions

  • BiologicalHaemophilus influenzae type b and meningococcal serogroup C (vaccine)

    One intramuscular dose at 12-18 months of age

    Also known as: Hib-MenC, Menitorix™

  • BiologicalPriorix™

    One subcutaneous dose at 12-18 months of age

  • BiologicalHiberix™

    One intramuscular dose at 12-18 months of age.

  • BiologicalMeningitec™

    One intramuscular dose at 12-18 months of age

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)

    Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of short-term protection.

    Time frame: 1 month after vaccination

  2. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Greater Than or Equal to 1:8 Titer

    rSBA-MenC titers greater than or equal to 1:8 titer are indicative of seroprotection.

    Time frame: 1 month after vaccination

Secondary outcomes

  1. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values

    rSBA-MenC titers cut-off values assessed were greater than or equal to (≥) 1:8 (indicative of seroprotection) and ≥ 1:128 titers. Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the Public Health England (PHE), formerly known as Health Protection Agency (HPA), at Year 4, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.

    Time frame: Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination

  2. Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values

    rSBA-MenC titers cut-off values assessed were greater than or equal to (≥)1:8 (indicative of seroprotection) and 1:128 titers. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.

    Time frame: 5 years after vaccination

  3. Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers

    Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the PHE at year 4 after vaccination, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.

    Time frame: Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination.

  4. Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers

    Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.

    Time frame: 5 years after vaccination

  5. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values

    Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).

    Time frame: Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination

  6. Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values

    Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).

    Time frame: 5 years after vaccination

  7. Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations

    Concentrations are given as Geometric Mean Concentrations (GMCs).

    Time frame: Prior to, 1 month , 1 year, 2 years, 3 years and 4 years after vaccination

  8. Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations

    Concentrations are given as Geometric Mean Concentrations (GMCs).

    Time frame: 5 years after vaccination

  9. Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Above the Cut-off Values

    Anti-PSC antibody concentration cut-off values assessed include greater than or equal to (≥) 0.30 µg/mL and ≥ 2.0 µg/mL.

    Time frame: Prior to, 1 month, 1 year, 2 years and 3 years after vaccination

  10. Anti-polysaccharide C (Anti-PSC) Antibody Concentrations

    Concentrations given as Geometric Mean Concentrations (GMCs).

    Time frame: Prior to, 1 month, 1 year, 2 years and 3 years after vaccination

  11. Number of Subjects Reporting Solicited Local and General Symptoms

    Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, fever (≥ 38°C), irritability and loss of appetite.

    Time frame: Within 4 days (Day 0 -Day 3) after vaccination

  12. Number of Subjects Reporting Unsolicited Symptoms

    Unsolicited symptom: Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.

    Time frame: Within 31 days (Day 0 - Day 30) after vaccination

  13. Number of Subjects Reporting Serious Adverse Events (SAEs)

    A serious adverse event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. For the long-term persistence phase (Years 1 through 5), only those SAEs that are determined by the investigator to have a causal relationship to the vaccination will be described individually.

    Time frame: Throughout the entire study period (up to year 5)

07

Results

Posted Oct 23, 2009

Participant flow

Active Phase
Participant flow — Active Phase
MilestoneMenitorix GroupMeningitec + Hiberix Group
Started324109
Completed320108
Not completed41
Withdrew: Withdrawal by subject41
Year 1 Follow-up
Participant flow — Year 1 Follow-up
MilestoneMenitorix GroupMeningitec + Hiberix Group
Started295100
Completed295100
Not completed00
Year 2 Follow-up
Participant flow — Year 2 Follow-up
MilestoneMenitorix GroupMeningitec + Hiberix Group
Started27092
Completed27092
Not completed00
Year 3 Follow-up
Participant flow — Year 3 Follow-up
MilestoneMenitorix GroupMeningitec + Hiberix Group
Started25689
Completed25689
Not completed00
Year 4 Follow-up
Participant flow — Year 4 Follow-up
MilestoneMenitorix GroupMeningitec + Hiberix Group
Started22880
Completed22880
Not completed00
Year 5 Follow up
Participant flow — Year 5 Follow up
MilestoneMenitorix GroupMeningitec + Hiberix Group
Started21778
Completed21778
Not completed00

Outcome measures

PrimaryNumber of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)

Anti-PRP antibody concentration greater than or equal to 0.15 µg/mL is indicative of short-term protection.

Time frame:
1 month after vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)
SubjectsMenitorix GroupMeningitec + Hiberix Group
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Greater Than or Equal to 0.15 Micrograms Per Milliliter (µg/mL)292100
PrimaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Greater Than or Equal to 1:8 Titer

rSBA-MenC titers greater than or equal to 1:8 titer are indicative of seroprotection.

Time frame:
1 month after vaccination
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Greater Than or Equal to 1:8 Titer
SubjectsMenitorix GroupMeningitec + Hiberix Group
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Greater Than or Equal to 1:8 Titer28098
SecondaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values

rSBA-MenC titers cut-off values assessed were greater than or equal to (≥) 1:8 (indicative of seroprotection) and ≥ 1:128 titers. Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the Public Health England (PHE), formerly known as Health Protection Agency (HPA), at Year 4, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.

Time frame:
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values
SubjectsMenitorix GroupMeningitec + Hiberix Group
≥ 1:8 [Prior to vaccination] (N=255, 83)377
≥ 1:8 [1 year after vaccination] (N=249, 89)21668
≥ 1:8 [2 years after vaccination] (N= 235, 86)16452
≥ 1:8 [3 years after vaccination] (N= 226, 77)14541
≥ 1:8 [4 years after vaccination] (N= 208, 73)269
≥ 1:128 [Prior to vaccination] (N=255, 83)153
≥ 1:128 [1 month after vaccination] (N=281, 98)24789
≥ 1:128 [1 year after vaccination] (N=249, 89)11737
≥ 1:128 [2 years after vaccination] (N= 235, 86)7626
≥ 1:128 [3 years after vaccination] (N= 226, 77)5822
≥ 1:128 [4 years after vaccination] (N= 208, 73)74
SecondaryNumber of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values

rSBA-MenC titers cut-off values assessed were greater than or equal to (≥)1:8 (indicative of seroprotection) and 1:128 titers. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.

Time frame:
5 years after vaccination
Reported as:
Number · Subjects
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers Above the Cut-off Values
SubjectsMenitorix GroupMeningitec + Hiberix Group
≥ 1:8 [5 years after vaccination]3717
≥ 1:128 [5 years after vaccination ]127
SecondaryMeningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers

Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at a GlaxoSmithKline (GSK) laboratory up to Year 3 after vaccination, titres were expressed as the reciprocal of the dilution resulting in 50% inhibition. For SBA testing at the PHE at year 4 after vaccination, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.

Time frame:
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination.
Reported as:
Geometric mean · Titer
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers
TiterMenitorix GroupMeningitec + Hiberix Group
Prior to vaccination (N= 255; 83)6.3 (5.5 to 7.3)5.5 (4.3 to 7.2)
1 month after vaccination (N= 281; 98)482.8 (420.7 to 554.2)621.0 (480.3 to 802.9)
1 year after vaccination (N= 249; 89)91.7 (75.6 to 111.3)63.8 (43.3 to 94.1)
2 years after vaccination (N= 235; 86)39.3 (31.3 to 49.3)30.6 (20.1 to 46.7)
3 years after vaccination (N= 226; 77)29.8 (23.6 to 37.6)21.8 (14.2 to 33.5)
4 years after vaccination (N=208;73)5.3 (4.7 to 6.0)6.0 (4.5 to 8.0)
SecondaryMeningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers

Titers are given as Geometric Mean Titers (GMTs). Functional anti-meningococcal serogroup C activity (SBA-MenC) was determined by a serum bactericidal test using rabbit complement. For SBA testing at the PHE at Year 5, titres were expressed as the reciprocal of the last dilution resulting in at least 50% inhibition.

Time frame:
5 years after vaccination
Reported as:
Geometric mean · Titer
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers
TiterMenitorix GroupMeningitec + Hiberix Group
Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titers6.6 (5.6 to 7.8)8.5 (5.9 to 12.3)
SecondaryNumber of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values

Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).

Time frame:
Prior to, 1 month, 1 year, 2 years, 3 years and 4 years after vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values
SubjectsMenitorix GroupMeningitec + Hiberix Group
≥ 0.15 µg/mL [Prior to vaccination] (N=285,98)21982
≥ 0.15 µg/mL [1 year post-vaccination] (N=255,91)25291
≥ 0.15 µg/mL [2 years post-vaccination] (N=237,84)23584
≥ 0.15 µg/mL [3 years post-vaccination] (N=233,78)23177
≥ 0.15 µg/mL [4 years post-vaccination] (N=204,73)20273
≥ 1.0 µg/mL [Prior to vaccination] (N=285,98)7722
≥ 1.0 µg/mL [1 month post-vaccination] (N=292,100)286100
≥ 1.0 µg/mL [1 year post-vaccination] (N=255,91)20980
≥ 1.0 µg/mL [2 years post-vaccination] (N=237,84)17472
≥ 1.0 µg/mL [3 years post-vaccination] (N=233,78)16464
≥ 1.0 µg/mL [4 years post-vaccination] (N=204,73)14457
SecondaryNumber of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values

Anti-PRP antibody concentration cut-off values assessed include 0.15 µg/mL (indicative of short-term protection) and 1.0 µg/mL (indicative of long-term protection).

Time frame:
5 years after vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentration Above Cut-off Values
SubjectsMenitorix GroupMeningitec + Hiberix Group
≥ 0.15 µg/mL [5 years post-vaccination]19167
≥ 1.0 µg/mL [5 years post-vaccination]12947
SecondaryAnti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations

Concentrations are given as Geometric Mean Concentrations (GMCs).

Time frame:
Prior to, 1 month , 1 year, 2 years, 3 years and 4 years after vaccination
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations
microgram per milliliter (µg/mL)Menitorix GroupMeningitec + Hiberix Group
Prior to vaccination (N=285, 98)0.438 (0.374 to 0.512)0.472 (0.364 to 0.611)
1 month after vaccination (N=292, 100)46.652 (38.929 to 55.907)73.976 (57.624 to 94.968)
1 year after vaccination (N=255, 91)3.550 (2.988 to 4.218)4.802 (3.708 to 6.218)
2 years after vaccination (N= 237, 84)2.5 (2.1 to 3.0)3.3 (2.5 to 4.2)
3 years after vaccination (N= 233, 78)2.234 (1.886 to 2.647)2.751 (2.113 to 3.582)
4 years after vaccination (N= 204, 73)2.116 (1.773 to 2.524)2.964 (2.215 to 3.966)
SecondaryAnti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations

Concentrations are given as Geometric Mean Concentrations (GMCs).

Time frame:
5 years after vaccination
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations
microgram per milliliter (µg/mL)Menitorix GroupMeningitec + Hiberix Group
Anti-polyribosylribitol Phosphate (Anti-PRP) Antibody Concentrations2.131 (1.752 to 2.592)2.537 (1.815 to 3.546)
SecondaryNumber of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Above the Cut-off Values

Anti-PSC antibody concentration cut-off values assessed include greater than or equal to (≥) 0.30 µg/mL and ≥ 2.0 µg/mL.

Time frame:
Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Reported as:
Number · Subjects
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Above the Cut-off Values
SubjectsMenitorix GroupMeningitec + Hiberix Group
≥ 0.3 µg/mL [prior to vaccination] (N=283, 96)21
≥ 0.3 µg/mL [1 month post-vaccination] (N=290,100)290100
≥ 0.3 µg/mL [1 year post-vaccination] (N=250, 91)9533
≥ 0.3 µg/mL [2 years post-vaccination] (N=233,84)4717
≥ 0.3 µg/mL [3 years post-vaccination] (N=230,79)248
≥ 2.0 µg/mL [prior to vaccination] (N=283, 96)00
≥ 2.0 µg/mL [1 month post-vaccination] (N=290,100)28996
≥ 2.0 µg/mL [1 year post-vaccination] (N=250, 91)60
≥ 2.0 µg/mL [2 years post-vaccination] (N=233,84)11
≥ 2.0 µg/mL [3 years post-vaccination] (N=230,79)11
SecondaryAnti-polysaccharide C (Anti-PSC) Antibody Concentrations

Concentrations given as Geometric Mean Concentrations (GMCs).

Time frame:
Prior to, 1 month, 1 year, 2 years and 3 years after vaccination
Reported as:
Geometric mean · micrograms per milliliter (µg/mL)
Anti-polysaccharide C (Anti-PSC) Antibody Concentrations
micrograms per milliliter (µg/mL)Menitorix GroupMeningitec + Hiberix Group
Prior to vaccination (N=283, 96)NA (NA to NA)NA (NA to NA)
1 month after vaccination (N=290,100)18.69 (17.10 to 20.42)7.95 (6.95 to 9.08)
1 year after vaccination (N=250, 91)NA (NA to 0.30)NA (NA to NA)
2 years after vaccination (N= 233, 84)0.2 (NA to NA)0.2 (NA to NA)
3 years after vaccination (N= 230, 79)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Subjects Reporting Solicited Local and General Symptoms

Solicited local symptoms assessed include pain, redness and swelling at the injection site. Solicited general symptoms assessed include drowsiness, fever (≥ 38°C), irritability and loss of appetite.

Time frame:
Within 4 days (Day 0 -Day 3) after vaccination
Reported as:
Number · Subjects
Number of Subjects Reporting Solicited Local and General Symptoms
SubjectsMenitorix GroupMeningitec + Hiberix Group
Pain9142
Redness14664
Swelling7841
Drowsiness10240
Fever7630
Irritabily15469
Loss of appetite10240
SecondaryNumber of Subjects Reporting Unsolicited Symptoms

Unsolicited symptom: Any adverse event (AE) reported in addition to those solicited during the clinical study. Also any solicited symptom with onset outside the specified period of follow-up for solicited symptoms will be reported as an unsolicited adverse event.

Time frame:
Within 31 days (Day 0 - Day 30) after vaccination
Reported as:
Number · Subjects
Number of Subjects Reporting Unsolicited Symptoms
SubjectsMenitorix GroupMeningitec + Hiberix Group
Number of Subjects Reporting Unsolicited Symptoms21781
SecondaryNumber of Subjects Reporting Serious Adverse Events (SAEs)

A serious adverse event (SAE) is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study subject. For the long-term persistence phase (Years 1 through 5), only those SAEs that are determined by the investigator to have a causal relationship to the vaccination will be described individually.

Time frame:
Throughout the entire study period (up to year 5)
Reported as:
Number · Subjects
Number of Subjects Reporting Serious Adverse Events (SAEs)
SubjectsMenitorix GroupMeningitec + Hiberix Group
Vaccination Phase (N=324, 109)42
Until year 5 (N=295, 100)00

Adverse events

Collected over Up to Year 5 for Serious Adverse Events. Within 31 days after vaccination for Other Adverse Events that were not systematically assessed. Within 4 days after vaccination for Other Adverse Events that were systematically assessed.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Menitorix Group—4/324 (1.2%)293/324 (90.4%)
Meningitec + Hiberix Group—2/109 (1.8%)104/109 (95.4%)
Most frequent serious events
Most frequent serious events
EventMenitorix GroupMeningitec + Hiberix Group
AsthmaRespiratory, thoracic and mediastinal disorders0/3241/109
PneumoniaInfections and infestations0/3241/109
PyrexiaGeneral disorders0/3241/109
RashSkin and subcutaneous tissue disorders0/3241/109
Breath holdingPsychiatric disorders1/3240/109
ConvulsionNervous system disorders1/3240/109
Croup infectiousInfections and infestations1/3240/109
GastroenteritisInfections and infestations1/3240/109
Traumatic brain injuryInjury, poisoning and procedural complications1/3240/109
Most frequent other events
Showing 10 of 17
Most frequent other events
EventMenitorix GroupMeningitec + Hiberix Group
IrritabilityGeneral disorders154/32469/109
RednessGeneral disorders146/32464/109
PainGeneral disorders91/32442/109
SwellingGeneral disorders78/32441/109
DrowsinessGeneral disorders102/32440/109
Loss of appetiteGeneral disorders102/32440/109
Fever (above or equal to 38 degrees Celsius)General disorders76/32430/109
Upper respiratory tract infectionInfections and infestations54/32413/109
RashSkin and subcutaneous tissue disorders24/32417/109
TeethingGastrointestinal disorders40/32415/109

Baseline characteristics

Age, Continuous
Age, Continuous(Months)Menitorix GroupMeningitec + Hiberix GroupTotal
Mean12.5 ± 0.9412.5 ± 0.7512.5 ± 0.90
Sex: Female, Male
Sex: Female, Male(Participants)Menitorix GroupMeningitec + Hiberix GroupTotal
Female15042192
Male17467241
08

Study locations

7 sites
  • GSK Investigational Site
    Garran, Australian Capital Territory 2606, Australia
  • GSK Investigational Site
    Randwick, New South Wales 2031, Australia
  • GSK Investigational Site
    Westmead, New South Wales 2145, Australia
  • GSK Investigational Site
    Herston, Queensland 4029, Australia
  • GSK Investigational Site
    North Adelaide, South Australia 5006, Australia
  • GSK Investigational Site
    Carlton, Victoria 3053, Australia
  • GSK Investigational Site
    Perth, Western Australia, Australia
09

References and documents

Publications

  • Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G, Ziegler JB, Heron L, Lambert S, Caubet M, Mesaros N, Boutriau D. Immediate and longer term immunogenicity of a single dose of the combined haemophilus influenzae type B-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in primed toddlers 12 to 18 months of age. Pediatr Infect Dis J. 2011 Apr;30(4):340-2. doi: 10.1097/INF.0b013e31820013d2. PubMed 21068692 ↗
  • Booy R, Richmond P, Nolan T, McVernon J, Marshall H, Nissen M, Reynolds G, Ziegler JB, Stoney T, Heron L, Lambert S, Mesaros N, Peddiraju K, Miller JM. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers. Pediatr Infect Dis J. 2013 Feb;32(2):169-74. doi: 10.1097/INF.0b013e3182787bff. PubMed 23080288 ↗
  • Booy R et al. Immunogenicity and safety of the Hib-MenC-TT conjugate vaccine in Hib-primed toddlers: 3 year follow-up. Abstract presented at the 7th World Congress for World Society for Pediatric Infectious Diseases (WSPID). Melbourne, Australia, 16-19 November 2011.
  • Booy R et al. Immunogenicity and safety of the Hib-MenC-TT conjugate vaccine in Hib-primed toddlers: 4 year follow-up. Abstract presented at the Communicable Diseases Network Australia - Communicable Diseases Control Conference 2013, Canberra, Australia, 19-20 March 2013.
  • Booy R et al. Prolonged immunogenicity and safety of the HibMenC-TT conjugate vaccine in Hib-Primed toddlers. Abstract presented at the PHAA Communicable Disease Conference. Canberra, Australia, 4-6 April 2011.

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2009, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2006
First posted
May 16, 2006
Start
Jun 1, 2006
Primary completionActual
Nov 1, 2007
CompletionActual
Nov 6, 2007
Results first posted
Oct 23, 2009
Last update
Aug 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00326118
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 16, 2006
Start date
Jun 1, 2006
Primary completion
Nov 1, 2007
Completion
Nov 6, 2007
Results posted
Oct 23, 2009
Last update
Aug 24, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion